Transient-native-transient reprogramming enables researchers to sidestep the differentiation quirks which can complicate the use of induced pluripotent stem cells by resetting their epigenetic memory.

Here, we outline some of the main trends anticipated in market growth and development for biologics in the next few years. The global biologics market is predicted to exceed $600bn by 2032, driven by demand for personalised treatments for chronic diseases.

Significant progress in iBio's in vivo preclinical programs with positive data from three antibody candidates: anti-EGFRvIII, CCR8, and TROP-2 x CD3.

The importance of validating hypotheses, understanding the biology of cancer progression, and utilising biomarkers in early screening to stratify populations and improve clinical endpoints.

A study from Duke University found that a lipid present in breast milk promotes a process leading to the generation of new brain cells, which could potentially aid in the repair of damaged white matter in infants with cerebral palsy.

Unveiling advancements in preclinical immuno-oncology: Exploring humanized mouse models and human knock-in mice for targeted cancer therapies.

How are oligo therapeutics revolutionising genetic disease treatments through precise targeting and transformative therapies? In this article, we explore how they provide precise gene expression interference for untreatable conditions by directly targeting disease-associated proteins and genetic mutations.

Improving process efficiency is a key approach to factor in when looking at how cell therapy manufacture can be made more sustainable.

We take a look at how the commercialisation of COVID-19 vaccines in the US will impact the price of the vital therapeutic.

The Pharma giants have partnered to advance the development of bispecific T cell engaging antibodies using WuXi’s platforms.

The collaboration includes an upfront payment, milestone-dependent funds, and commercial royalties for F-star.

An introduction to the various cell types in the immune system and the opportunities to harness them in immuno-oncology therapies.